Carmen Chang has bought stock on 11 days since May 2019
10% owner at Korro Bio, Inc., and 9 other companies
SEC CIK 0001746342 · Filings on SEC.gov ↗
Carmen Chang's record
3 months after each buy, from the first price a copier could get.
6 buys since 2019 with 3 months of prices.
Companies
- KRRO Korro Bio, Inc.10% owner
- SGP SpyGlass Pharma, Inc.10% owner
- MBX MBX Biosciences, Inc.10% owner
- SVRA Savara Inc.10% owner
- GNCA Genocea Biosciences, Inc.10% owner
- TRVI Trevi Therapeutics, Inc.10% owner
- MTCR Metacrine, Inc.10% owner
- MRKR Marker Therapeutics, Inc.10% owner
- RGLS Regulus Therapeutics Inc.10% owner
- AKUS Akouos, Inc.10% owner
Every filing
13 filings since May 2019, newest first
Korro Bio, Inc.
10% owner
Spyglass Pharma, Inc.
10% owner
Mbx Biosciences, Inc.
10% owner
Korro Bio, Inc.
10% owner
Savara Inc
10% owner
Genocea Biosciences, Inc.
10% owner
Trevi Therapeutics, Inc.
10% owner
Metacrine, Inc.
10% owner
Marker Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
Akouos, Inc.
10% owner
Trevi Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
About Carmen Chang
Carmen Chang is a prominent venture capital investor and 10% owner of SpyGlass Pharma, Inc. (SGP), holding approximately 7,392,301 shares valued at over $205 million as of recent filings.( She recently participated in a significant share purchase on February 9, 2026, acquiring shares at $16 each alongside other insiders and executives, signaling strong confidence in the company's future.(
Chang serves as a manager of general partner entities associated with her investments and maintains substantial stakes across multiple biotech firms, including Mirum Pharmaceuticals Inc. (MIRM) with 4,186,243 shares worth $188 million, Savara Inc. (SVRA) with 24,471,264 shares worth $75 million, and Trevi Therapeutics Inc. (TRVI) with 11,370,376 shares.( Her portfolio spans 15 companies, such as Akouos Inc., MBX Biosciences Inc., and Coursera Inc., with her estimated net worth exceeding $478 million as of 2025.( SEC filings confirm her role as a 10% owner in SpyGlass Pharma through beneficial ownership structures.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.